目的 觀察無水乙醇腹腔神經(jīng)叢阻滯術(shù)對晚期胰腺癌頑固性疼痛的鎮(zhèn)痛效果、并發(fā)癥發(fā)生及患者生存質(zhì)量的影響。方法 選取2001年1月至2005年9月61例晚期胰腺癌伴頑固性疼痛及消化道梗阻無法行根治手術(shù)的患者，在行姑息性手術(shù)的同時(shí)，行腹腔神經(jīng)叢無水乙醇阻滯治療，觀察術(shù)后3個(gè)月內(nèi)疼痛緩解、生存質(zhì)量評分（KPS）的變化及不良反應(yīng)。結(jié)果 治療后1周內(nèi)全部患者頑固性疼痛癥狀明顯緩解 (P＜0.05)， KPS評分顯著提高 (P＜0.05)。隨診3個(gè)月，術(shù)后86.5% (45/52) 患者無痛或僅輕度疼痛，治療過程中和治療后未發(fā)生嚴(yán)重并發(fā)癥。結(jié)論 無水乙醇腹腔神經(jīng)叢阻滯治療晚期胰腺癌頑固性疼痛能較好地緩解其癥狀，改善患者生存質(zhì)量，近期療效確切，安全性高。
引用本文： 熊炯炘,黃鵬,陶京,王春友,吳河水. 腹腔神經(jīng)叢阻滯術(shù)治療晚期胰腺癌頑固性疼痛的臨床研究. 中國普外基礎(chǔ)與臨床雜志, 2006, 13(5): 515-517. doi: 復(fù)制
| 1. | Wanebo HJ, Vezeridis MP. Pancreatic carcinoma in perspective. A continuing challenge [Ｊ]. Cancer， 1996； 78(3 Supple)∶580. |
| 2. | Brennan MF, Moccia RD, Klimstra D. Management of adenocarcinoma of the body and tail of the pancreas [Ｊ]. Ann Surg, 1996； 223(5)∶506. |
| 3. | 孫 燕, 顧慰萍. 癌癥三階梯止痛指導(dǎo)原則 [M]. 北京： 北京醫(yī)科大學(xué)出版社, 2000∶12～16. |
| 4. | Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreas cancer: a randomized trial [Ｊ]. J Clin Oncol, 1997； 15(6) ∶2403. |
| 5. | World Health Organization. Handbook for reporting results of cance treatment. World Health Organization. Genvae, 1976∶16-21. |
| 6. | Kita Y, Tanaka T, Yoshida S, et al. Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model [Ｊ]. Vaccine, 2005； 23 (17-18)∶2132. |
| 7. | 王春友. 重視胰腺癌分期評估及綜合治療的科學(xué)抉擇 [Ｊ]. 中國實(shí)用外科雜志， 2004； 24( 5) ∶259. |
| 8. | Storniolo AM, Enas NH, Brown CA, et al. An investigational new drug treatment program for patients with gemcitabine: results for over 3 000 patients with pancreatic carcinoma [Ｊ]. Cancer, 1999； 85(6)∶1261. |
| 9. | 王 平, 陶 凡, 鄭漢光. 腹腔神經(jīng)阻滯用于晚期癌性疼痛的療效觀察 [Ｊ]. 中國疼痛醫(yī)學(xué)雜志, 2003； 9(2)∶117. |
| 10. | Popiela T, Kedra B, Sierzega M, et al. Surgical palliation for pancreatic cancer. The 25-year experience of a single reference centre [Ｊ]. Zentralbl Chir, 2002； 127(11)∶965. |
- 1. Wanebo HJ, Vezeridis MP. Pancreatic carcinoma in perspective. A continuing challenge [Ｊ]. Cancer， 1996； 78(3 Supple)∶580.
- 2. Brennan MF, Moccia RD, Klimstra D. Management of adenocarcinoma of the body and tail of the pancreas [Ｊ]. Ann Surg, 1996； 223(5)∶506.
- 3. 孫 燕, 顧慰萍. 癌癥三階梯止痛指導(dǎo)原則 [M]. 北京： 北京醫(yī)科大學(xué)出版社, 2000∶12～16.
- 4. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreas cancer: a randomized trial [Ｊ]. J Clin Oncol, 1997； 15(6) ∶2403.
- 5. World Health Organization. Handbook for reporting results of cance treatment. World Health Organization. Genvae, 1976∶16-21.
- 6. Kita Y, Tanaka T, Yoshida S, et al. Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model [Ｊ]. Vaccine, 2005； 23 (17-18)∶2132.
- 7. 王春友. 重視胰腺癌分期評估及綜合治療的科學(xué)抉擇 [Ｊ]. 中國實(shí)用外科雜志， 2004； 24( 5) ∶259.
- 8. Storniolo AM, Enas NH, Brown CA, et al. An investigational new drug treatment program for patients with gemcitabine: results for over 3 000 patients with pancreatic carcinoma [Ｊ]. Cancer, 1999； 85(6)∶1261.
- 9. 王 平, 陶 凡, 鄭漢光. 腹腔神經(jīng)阻滯用于晚期癌性疼痛的療效觀察 [Ｊ]. 中國疼痛醫(yī)學(xué)雜志, 2003； 9(2)∶117.
- 10. Popiela T, Kedra B, Sierzega M, et al. Surgical palliation for pancreatic cancer. The 25-year experience of a single reference centre [Ｊ]. Zentralbl Chir, 2002； 127(11)∶965.